FDA

Trump Announces Dismissal of FDA Commissioner Makary Summary: President Trump has announced the dismissal of FDA Commissioner Robert Makary, citing policy disagreements with the White House. According to Reuters, U.S. President Trump has announced the dismissal of Food and Drug Administration (FDA) Commissioner Robert Makary. Makary, a prominent surgeon and public health researcher formerly at Johns Hopkins University, was nominated to lead the FDA in 2025. During his tenure, he advanced several drug approval reforms. ...

The White House is preparing to replace FDA Commissioner Marty Makary as the agency faces internal turmoil and credibility challenges.

White House Prepares to Replace FDA Commissioner Makary Amid Agency Turmoil The White House is preparing to replace FDA Commissioner Marty Makary, according to The Washington Post. President Trump has signed off on the ouster, senior officials confirmed. Makary’s tenure has been marked by internal policy disputes and personnel turmoil at the agency. The leadership change signals a potential shift in the FDA’s regulatory direction. Source: The Washington Post, Google News ...

[Brief] Trump Plans to Fire FDA Commissioner Marty Makary The New York Times reports that Trump has approved the dismissal of FDA Commissioner Marty Makary. This personnel change could shift the direction of US Food and Drug Administration policy. Makary has played a key role in drug approval and public health policy since taking office. A senior official confirmed Trump has signed off on the decision. Source: NYT

FDA Vaccine Studies Censored by Trump Administration After Finding Benefits of Shots According to a report by Ars Technica, the Trump administration reportedly blocked the U.S. Food and Drug Administration (FDA) from publishing research findings that demonstrated the benefits of vaccines – a move that has sparked strong concerns in the public health community. What Happened The report alleges that FDA researchers completed multiple studies showing positive vaccine outcomes, but these findings were subject to government-level intervention and censorship before publication. ...

The FDA has withdrawn multiple studies that had found Covid and shingles vaccines to be safe, raising concerns in the public health community.

The FDA commissioner publicly defended the agency’s drug approval decisions, responding to criticism from pharmaceutical companies and some lawmakers, emphasizing that approval standards will not be lowered under political pressure.

The FDA approves expanded access to daraxonrasib, the first RAS-targeting inhibitor for pancreatic cancer, which has shown promise in extending survival for metastatic patients in clinical trials.

The FDA has granted expanded access to Revolution Medicines’ targeted pancreatic cancer drug daraxonrasib, opening a pathway for more patients to receive a therapy that has shown promising results in clinical trials.

The U.S. FDA approves expanded access to daraxonrasib, a breakthrough targeted therapy for previously treated metastatic pancreatic ductal adenocarcinoma, offering new hope for patients with one of the deadliest cancers.